600671 Hangzhou Tianmushan Pharmaceutical Enterprise
- 7.87
- +0.15+1.94%
Hangzhou Tianmushan Pharmaceutical Enterprise News
Announcement from Hangzhou Tianmushan Pharmaceutical Co., Ltd. regarding the settlement of irregular guarantee matters.
Announcement of resolutions of the first meeting of the twelfth board of directors of Hangzhou Tianmu Shan Pharmaceutical Joint Stock Co., Ltd.
Announcement of the resolution of the first meeting of the twelfth board of supervisors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement on the convening of the 2023 Performance Explanation Meeting of Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd.
Reply to the inquiry letter on the information disclosure of the annual report of Hangzhou Tianmushan Pharmaceutical Co., Ltd. for the year 2023 from the Yunitai Zhenqing Certified Public Accountants (special general partnership).
Announcement of the resolution of the 32nd meeting of the 11th board of directors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of the resolution of the 25th meeting of the 11th Supervisory Board of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 24th Meeting of the 11th Board of Supervisors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 31st Meeting of the 11th Board of Directors of Hangzhou Tianmusan Pharmaceutical Co., Ltd.
Independent Director Candidate Statements and Commitments (Pei Yang)
Independent Director Candidate Statements and Commitments (Sheng Xiaowei)
Independent Director Nominee's Statement and Commitment (Huilong Huaze)
Independent Director Nominee Statement and Commitment (Yuanjia Healthcare)
Announcement of Resolutions of the 23rd Meeting of the 11th Board of Supervisors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 30th Meeting of the 11th Board of Directors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on receiving the Shanghai Stock Exchange's “Inquiry Letter on the Company's 2023 Annual Report Information Disclosure”
Announcement of Hangzhou Tianmusan Pharmaceutical Co., Ltd. on holding the 2023 annual results briefing
2023 Independent Director Debriefing Report (Gai Yongmei)
2023 Independent Director Debriefing Report (Zhao Xiang)
Opinions of the Board of Supervisors on the “Special Instructions of the Board of Directors on the Issuance of Internal Control Audit Reports by Accounting Firms with Unqualified Opinions on Highlighted Matters”
Analysis
Price Target
No Data
